BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Aphrothiti J. Hanrahan, Ziyu Chen, Neal Rosen, David B. Solit
Topics & Concepts
TrametinibDabrafenibMEK inhibitorCancer researchMedicineDrug resistanceVemurafenibPopulationMutantMAPK/ERK pathwayCancerCarcinogenesisTargeted therapyOncologyBiologyInternal medicineKinaseMelanomaGeneGeneticsEnvironmental healthMetastatic melanomaMelanoma and MAPK PathwaysColorectal Cancer Treatments and StudiesCancer Mechanisms and Therapy